Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages, Alveolar | 1 | 2021 | 57 | 0.760 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 135 | 0.740 |
Why?
|
| Monocytes | 1 | 2021 | 217 | 0.710 |
Why?
|
| Homeostasis | 1 | 2021 | 408 | 0.670 |
Why?
|
| Cancer-Associated Fibroblasts | 4 | 2022 | 36 | 0.610 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 127 | 0.590 |
Why?
|
| beta Catenin | 2 | 2014 | 266 | 0.510 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 450 | 0.500 |
Why?
|
| Lung | 1 | 2021 | 1243 | 0.490 |
Why?
|
| Th17 Cells | 2 | 2014 | 84 | 0.480 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 440 | 0.460 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 155 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 1256 | 0.420 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1518 | 0.390 |
Why?
|
| Colitis | 1 | 2014 | 241 | 0.380 |
Why?
|
| Stromal Cells | 3 | 2021 | 150 | 0.370 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 94 | 0.370 |
Why?
|
| Colon | 1 | 2014 | 505 | 0.370 |
Why?
|
| Signal Transduction | 3 | 2021 | 3368 | 0.350 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 566 | 0.340 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 2538 | 0.310 |
Why?
|
| Cathepsins | 1 | 2007 | 21 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 3202 | 0.290 |
Why?
|
| Cysteine Endopeptidases | 1 | 2007 | 88 | 0.290 |
Why?
|
| T-Lymphocytes | 5 | 2022 | 1221 | 0.270 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 290 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 421 | 0.250 |
Why?
|
| Mice | 9 | 2023 | 11710 | 0.250 |
Why?
|
| Cell Proliferation | 5 | 2021 | 1647 | 0.240 |
Why?
|
| Fibroblasts | 3 | 2023 | 755 | 0.240 |
Why?
|
| Up-Regulation | 1 | 2007 | 729 | 0.240 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 270 | 0.240 |
Why?
|
| Membrane Proteins | 3 | 2020 | 1214 | 0.240 |
Why?
|
| Cell Lineage | 2 | 2021 | 291 | 0.210 |
Why?
|
| Gelatinases | 2 | 2020 | 10 | 0.210 |
Why?
|
| Cellular Senescence | 1 | 2023 | 103 | 0.210 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 431 | 0.200 |
Why?
|
| Apoptosis | 4 | 2021 | 1718 | 0.200 |
Why?
|
| Serine Endopeptidases | 2 | 2020 | 146 | 0.200 |
Why?
|
| Isoantigens | 1 | 2021 | 71 | 0.200 |
Why?
|
| Neoplasms | 3 | 2023 | 3009 | 0.200 |
Why?
|
| Interleukin-6 | 1 | 2023 | 260 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 2 | 2020 | 322 | 0.200 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2021 | 20 | 0.190 |
Why?
|
| COS Cells | 1 | 2021 | 167 | 0.190 |
Why?
|
| Myeloid Cells | 1 | 2021 | 100 | 0.190 |
Why?
|
| Lymphocyte Activation | 2 | 2014 | 747 | 0.190 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 289 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 589 | 0.180 |
Why?
|
| Interleukin-8 | 1 | 2020 | 86 | 0.180 |
Why?
|
| Animals | 10 | 2023 | 27233 | 0.180 |
Why?
|
| Pharmacogenomic Variants | 1 | 2020 | 42 | 0.170 |
Why?
|
| Bone Marrow | 1 | 2021 | 445 | 0.170 |
Why?
|
| Proteomics | 1 | 2021 | 228 | 0.170 |
Why?
|
| Myofibroblasts | 1 | 2019 | 46 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 612 | 0.170 |
Why?
|
| Lymph Nodes | 2 | 2021 | 548 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 112 | 0.160 |
Why?
|
| Aging | 1 | 2023 | 712 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 389 | 0.150 |
Why?
|
| T Cell Transcription Factor 1 | 2 | 2014 | 23 | 0.150 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1571 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2014 | 80 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 1096 | 0.140 |
Why?
|
| Intestines | 1 | 2020 | 416 | 0.140 |
Why?
|
| Cell Line | 1 | 2021 | 2498 | 0.140 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1988 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1520 | 0.140 |
Why?
|
| Humans | 13 | 2023 | 88611 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2014 | 19 | 0.120 |
Why?
|
| Genes, APC | 1 | 2014 | 26 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 759 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 2406 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 659 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2346 | 0.110 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2014 | 76 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 970 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2013 | 79 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 97 | 0.110 |
Why?
|
| CD4 Antigens | 1 | 2012 | 83 | 0.110 |
Why?
|
| Lymphoma | 1 | 2013 | 264 | 0.100 |
Why?
|
| Transgenes | 1 | 2012 | 185 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 447 | 0.100 |
Why?
|
| Binding Sites | 1 | 2014 | 1113 | 0.100 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2011 | 61 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 302 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2011 | 105 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2336 | 0.090 |
Why?
|
| Machine Learning | 2 | 2023 | 242 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 520 | 0.090 |
Why?
|
| Endopeptidases | 2 | 2020 | 117 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 637 | 0.080 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 141 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2011 | 269 | 0.080 |
Why?
|
| Prognosis | 3 | 2021 | 3750 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 956 | 0.080 |
Why?
|
| Base Sequence | 2 | 2013 | 2331 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1240 | 0.080 |
Why?
|
| Cathepsin L | 1 | 2007 | 7 | 0.070 |
Why?
|
| Cytokines | 1 | 2011 | 801 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 3029 | 0.070 |
Why?
|
| Female | 5 | 2021 | 45759 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2023 | 661 | 0.070 |
Why?
|
| Response Elements | 1 | 2007 | 65 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2879 | 0.070 |
Why?
|
| Cell Survival | 2 | 2021 | 980 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2007 | 265 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2980 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 960 | 0.060 |
Why?
|
| Male | 3 | 2021 | 42012 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 1086 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2020 | 656 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 51 | 0.050 |
Why?
|
| Gene Knock-In Techniques | 1 | 2021 | 29 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 1977 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 178 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 21 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 182 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 308 | 0.040 |
Why?
|
| Multigene Family | 1 | 2020 | 203 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1057 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 214 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 289 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 200 | 0.040 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 81 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2020 | 215 | 0.040 |
Why?
|
| Pericytes | 1 | 2018 | 13 | 0.040 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2020 | 169 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 1883 | 0.040 |
Why?
|
| Stem Cells | 1 | 2020 | 371 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2018 | 279 | 0.040 |
Why?
|
| Phenotype | 1 | 2023 | 2435 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1542 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 542 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 434 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 623 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 804 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1427 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 634 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1142 | 0.030 |
Why?
|
| Genes, RAG-1 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Thymocytes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2837 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2013 | 66 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 266 | 0.030 |
Why?
|
| Integrases | 1 | 2012 | 60 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2012 | 73 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2012 | 115 | 0.030 |
Why?
|
| Histones | 1 | 2013 | 327 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2012 | 168 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 441 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 309 | 0.020 |
Why?
|
| DNA Repair | 1 | 2013 | 359 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 431 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1156 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 8178 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 18932 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 26348 | 0.010 |
Why?
|